BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23986641)

  • 1. Effect of transarterial chemoembolization with miriplatin plus epirubicin on local control of hepatocellular carcinoma: a retrospective comparison with miriplatin monotherapy.
    Hashimoto N; Iwazawa J; Ohue S; Mitani T
    Onco Targets Ther; 2013; 6():1025-30. PubMed ID: 23986641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local tumor progression following lipiodol-based targeted chemoembolization of hepatocellular carcinoma: a retrospective comparison of miriplatin and epirubicin.
    Iwazawa J; Ohue S; Hashimoto N; Mitani T
    Cancer Manag Res; 2012; 4():113-9. PubMed ID: 22570565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma.
    Tawada A; Chiba T; Ooka Y; Kanogawa N; Saito T; Motoyama T; Ogasawara S; Suzuki E; Kanai F; Yoshikawa M; Yokosuka O
    Anticancer Res; 2015 Jan; 35(1):549-54. PubMed ID: 25550601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial safety and outcomes of miriplatin plus low-dose epirubicin for transarterial chemoembolisation of hepatocellular carcinoma.
    Iwazawa J; Hashimoto N; Ohue S; Mitani T
    Anticancer Res; 2012 Nov; 32(11):5039-44. PubMed ID: 23155276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.
    Ikeda M; Kudo M; Aikata H; Nagamatsu H; Ishii H; Yokosuka O; Torimura T; Morimoto M; Ikeda K; Kumada H; Sato T; Kawai I; Yamashita T; Horio H; Okusaka T;
    J Gastroenterol; 2018 Feb; 53(2):281-290. PubMed ID: 28766016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcatheter arterial chemoembolization for hepatocellular carcinoma: Comparison of the therapeutic efficacies between miriplatin and epirubicin.
    Handa T; Imai Y; Sugawara K; Chikayama T; Nakazawa M; Ando S; Hamaoka K; Inao M; Nakayama N; Mochida S
    Hepatol Res; 2014 Oct; 44(11):1072-80. PubMed ID: 23957866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.
    Shirono T; Iwamoto H; Niizeki T; Shimose S; Nakano M; Satani M; Okamura S; Noda Y; Kamachi N; Kuromatsu R; Sakai M; Nomiyama M; Kuwano T; Tanaka M; Koga H; Torimura T
    Oncology; 2019; 96(2):79-86. PubMed ID: 30293080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoembolization-induced arterial damage: Evaluation of three different chemotherapeutic protocols using epirubicin and miriplatin.
    Iwazawa J; Hashimoto N; Ohue S; Muramoto O; Mitani T
    Hepatol Res; 2014 Feb; 44(2):201-8. PubMed ID: 23551984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective, randomized, controlled study of the efficacy of transcatheter arterial chemoembolization with miriplatin for hepatocellular carcinoma.
    Kubota K; Hidaka H; Nakazawa T; Okuwaki Y; Yamane K; Inoue T; Uojima H; Takada J; Tanaka Y; Shibuya A; Fujii K; Woodhams R; Matsunaga K; Kokubu S; Koizumi W
    Hepatol Res; 2018 Feb; 48(3):E98-E106. PubMed ID: 28656607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short-term results.
    Ogawa M; Takayasu K; Hirayama M; Miura T; Shiozawa K; Abe M; Matsumoto N; Nakagawara H; Ohshiro S; Yamamoto T; Tanaka N; Moriyama M; Mutou H; Yamamoto Y; Irie T
    Hepatol Res; 2016 Mar; 46(3):E60-9. PubMed ID: 25974615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch to miriplatin for multinodular hepatocellular carcinoma unresponsive to transarterial chemoembolization with epirubicin: a prospective study.
    Goda Y; Morimoto M; Irie K; Kobayashi S; Ueno M; Moriya S; Tezuka S; Ohkawa S; Morinaga S; Numata K; Tanaka K; Maeda S
    Jpn J Clin Oncol; 2017 Dec; 47(12):1151-1156. PubMed ID: 28977459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.
    Imai N; Ikeda K; Seko Y; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Oncology; 2011; 80(3-4):188-94. PubMed ID: 21709428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved survival with double platinum therapy transcatheter arterial infusion using cisplatin and transcatheter arterial chemoembolization using miriplatin for BCLC-B hepatocellular carcinoma.
    Ishikawa T; Abe S; Watanabe T; Nozawa Y; Sano T; Iwanaga A; Seki K; Honma T; Yoshida T
    Mol Clin Oncol; 2016 Nov; 5(5):511-516. PubMed ID: 27882236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma.
    Miyayama S; Yamashiro M; Shibata Y; Hashimoto M; Yoshida M; Tsuji K; Toshima F; Matsui O
    Jpn J Radiol; 2012 Apr; 30(3):263-70. PubMed ID: 22223074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of epirubicin hydrochloride and miriplatin hydrate as anticancer agents for transcatheter arterial chemoembolization of hepatocellular carcinoma.
    Aramaki T; Moriguchi M; Bekku E; Asakura K; Sawada A; Endo M
    Hepatol Res; 2013 May; 43(5):475-80. PubMed ID: 23046493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma.
    Okimoto K; Ogasawara S; Chiba T; Ooka Y; Oobu M; Azemoto R; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Yoshikawa M; Yokosuka O
    Anticancer Res; 2013 Dec; 33(12):5603-9. PubMed ID: 24324105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma.
    Okabe K; Beppu T; Haraoka K; Oh-Uchida Y; Yamamura S; Tomiyasu S; Yamanaka T; Sano O; Masuda T; Chikamoto A; Fujiyama S; Baba H
    Anticancer Res; 2011 Sep; 31(9):2983-8. PubMed ID: 21868548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma.
    Seko Y; Ikeda K; Kawamura Y; Fukushima T; Hara T; Sezaki H; Hosaka T; Akuta N; Suzuki F; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Kumada H
    Hepatol Res; 2013 Sep; 43(9):942-9. PubMed ID: 23301851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term efficacy of transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for hepatocellular carcinoma: comparison with conventional transarterial chemoembolization.
    Morimoto M; Kobayashi S; Moriya S; Ueno M; Tezuka S; Irie K; Goda Y; Ohkawa S
    Abdom Radiol (NY); 2017 Feb; 42(2):612-619. PubMed ID: 27624498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effect of arterial embolization with warmed miriplatin for multiple hepatocellular carcinoma.
    Ikeda K; Kawamura Y; Kobayashi M; Fujiyama S; Sezaki H; Hosaka T; Akuta N; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Hepatol Res; 2017 Jun; 47(7):632-640. PubMed ID: 27487085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.